Related Experiment Video
Updated: Aug 2, 2026
09:09
Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
Published on: September 20, 2016
SNC 80 and related delta opioid agonists
1Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, USA. CALDERONS@cder.fda.gov
Current Pharmaceutical Design
|March 23, 2004
Summary
Researchers explored the structure-activity relationships (SAR) of novel delta-opioid agonists, like SNC 80. This review details the development of diarylmethylpiperazine ligands and highlights remaining research questions in opioid research.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Neuroscience
Background:
- Selective delta (δ) opioid agonists, such as SNC 80 and BW373U86, represent a significant advancement in opioid ligand development.
- These compounds feature a unique diarylmethylpiperazine structure, distinguishing them from traditional morphinan-based opioids.
Purpose of the Study:
- To review the development of structure-activity relationships (SAR) for diarylmethylpiperazine delta-opioid ligands.
- To compare the SAR of diarylmethylpiperazines with established morphinan-based delta opioids.
- To identify and discuss unanswered questions in the field of delta-opioid ligand research.
Main Methods:
- Literature review of published studies on diarylmethylpiperazine opioid ligands.
- Analysis of structure-activity relationship data for SNC 80 and related compounds.
- Comparative analysis of pharmacological profiles between different classes of delta-opioid agonists.
Main Results:
- Detailed elucidation of SAR for the diarylmethylpiperazine class of delta-opioid agonists.
- Comparative insights into the pharmacological differences between diarylmethylpiperazines and morphinans.
- Identification of key structural features contributing to delta-opioid receptor selectivity and activity.
Conclusions:
- The diarylmethylpiperazine scaffold offers a promising avenue for developing selective delta-opioid ligands.
- Further research is needed to fully understand the SAR and therapeutic potential of this ligand class.
- Unanswered questions remain regarding the precise mechanisms and applications of these unique opioid agonists.
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...